nuclear-medicine-radiation-therapy-2018-tracks

4 / 20

Page 24
Journal of Medical Physics and Applied Sciences
ISSN: 2574-285X
I n t e r n a t i o n a l C o n f e r e n c e o n
Nuclear Medicine &
Radiation Therapy
Nuclear Medicine & Radiation Therapy 2018
O c t o b e r 0 1 - 0 2 , 2 0 1 8
S t o c k h o l m , S w e d e n
Biography
Harry Hendrikse has studied Pharmacy at the State University
of Utrecht (PharmD). He completed his PhD at the State Univer-
sity Groningen (The Netherlands) by measuring MDR in tumour
tissue using positron emission tomography (PET). Subsequent-
ly he was Postdoctoral Fellow at the PET Center of the Univer-
sity of Washington Medical Center (Seattle, USA). He has spe-
cialized as Hospital Pharmacist and Clinical Pharmacologist at
the University Hospital Groningen (UMCG) where he worked for
more than 10 years. Now he is working at VU University Med-
ical Center Amsterdam (VUmc) where he is Staff Member of
the Departments of Clinical Pharmacology and Pharmacy, Ra-
diology and Nuclear Medicine. He is also Professor in Clinical
Radiopharmacology VU University Medical Center Amsterdam.
He focusses on Labelling and Clinical PET Evaluation of Small
Molecules andMonoclonal Antibodies in Oncology. He has pub-
lished many peer reviewed manuscripts. He is a (Board) Mem-
ber of several scientific (inter)national programs andMember of
the Editorial Board of several scientific journals.
Radiolabeled drugs and PET imaging for personalized medicine
N H Hendrikse
VU University Medical Center, The Netherlands
N H Hendrikse, J. med phys & appl sci 2018, Volume: 3
DOI: 10.21767/2574-285X-C1-002
Therapeutic advances in cancer care have revolutionized the oncological
landscape. One of the major advancements in this regard is owed to the
development of targeted drug therapies. However, for successful clinical treatment
of cancer patients with these drugs, proper identification of target (e.g. receptor)
expression is essential. To have knowledge about target expression, tumour
biopsies have to be obtained, which is often limited by practical issues, including
the inability to reach the tumour, low yields of malignant tumour cells, or tumour
heterogeneity. Positron emission tomography (PET), a powerful and accessible
imaging technique, enables to overcome these limitations. PET can visualize
and quantify tumour specific uptake of radiolabelled targeting drugs, allowing
for characterization of their pharmacological and pharmacokinetic behaviour.
For visualization tumour targeting with PET, tyrosine kinase inhibitors (TKIs)
and monoclonal antibodies (mAbs) are most frequently used therapies. Due to
receptormutations in tumour tissue, the affinity of drugs for receptorsmay change,
often resulting in limited clinical response. Therefore, to select the best drug for
treatment for each patient, we radioactively labelled several TKIs and mAbs that
are in clinical use and performed PET studies to determine pharmacological
parameters, including receptor binding. PET also plays an important role to
optimize dose schemes in treatment of cancer patients. Cancer patients mostly
use different drugs simultaneously. Optimization of co-administration of drugs
is essential for successful tumour treatment. Several examples demonstrating
the role of quantitative PET imaging for receptor expression and mutation in
tumour tissue, but also optimization of chemotherapeutic dose schemes will be
discussed. Microdosing-PET provides a means for optimizing drug treatment
in individual cancer patients, and as such would be an important step towards
personalized medicine.